Analysts Expect Alimera Sciences Inc (ALIM) Will Announce Quarterly Sales of $11.68 Million

Wall Street analysts expect Alimera Sciences Inc (NASDAQ:ALIM) to announce $11.68 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Alimera Sciences’ earnings, with the highest sales estimate coming in at $12.15 million and the lowest estimate coming in at $11.20 million. Alimera Sciences posted sales of $9.14 million during the same quarter last year, which suggests a positive year-over-year growth rate of 27.8%. The business is expected to issue its next earnings results on Wednesday, February 27th.

On average, analysts expect that Alimera Sciences will report full year sales of $43.53 million for the current year, with estimates ranging from $43.06 million to $44.00 million. For the next fiscal year, analysts anticipate that the firm will report sales of $55.48 million, with estimates ranging from $50.70 million to $60.25 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Alimera Sciences.

Alimera Sciences (NASDAQ:ALIM) last announced its earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.01. The business had revenue of $11.14 million for the quarter, compared to the consensus estimate of $11.12 million.

ALIM has been the topic of a number of analyst reports. HC Wainwright set a $3.00 price target on shares of Alimera Sciences and gave the stock a “buy” rating in a research note on Thursday, September 6th. Cowen reiterated a “buy” rating and issued a $3.00 price target on shares of Alimera Sciences in a research note on Wednesday, September 5th. Zacks Investment Research upgraded shares of Alimera Sciences from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research note on Friday, November 9th. Finally, TheStreet upgraded shares of Alimera Sciences from a “d-” rating to a “c-” rating in a research note on Tuesday, November 6th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Alimera Sciences presently has a consensus rating of “Buy” and an average price target of $2.50.

A number of large investors have recently modified their holdings of the business. B. Riley Financial Inc. purchased a new position in Alimera Sciences in the 3rd quarter worth about $447,000. Renaissance Technologies LLC raised its position in Alimera Sciences by 27.7% in the 3rd quarter. Renaissance Technologies LLC now owns 732,790 shares of the biopharmaceutical company’s stock worth $718,000 after buying an additional 158,790 shares during the last quarter. Royce & Associates LP purchased a new position in Alimera Sciences in the 3rd quarter worth about $195,000. Stonepine Capital Management LLC raised its position in Alimera Sciences by 13.0% in the 2nd quarter. Stonepine Capital Management LLC now owns 6,981,184 shares of the biopharmaceutical company’s stock worth $6,830,000 after buying an additional 801,151 shares during the last quarter. Finally, BlackRock Inc. raised its position in Alimera Sciences by 28.5% in the 2nd quarter. BlackRock Inc. now owns 272,248 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 60,327 shares during the last quarter. 52.02% of the stock is owned by institutional investors and hedge funds.

Alimera Sciences stock traded up $0.03 during mid-day trading on Monday, reaching $1.02. The stock had a trading volume of 66,164 shares, compared to its average volume of 63,752. The stock has a market cap of $69.38 million, a price-to-earnings ratio of -3.52 and a beta of 1.63. Alimera Sciences has a one year low of $0.74 and a one year high of $1.38.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Recommended Story: How analysts view the yield curve

Get a free copy of the Zacks research report on Alimera Sciences (ALIM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit